stockrowAgenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
- Revenue
- +4.14%
- EPS
- −99.0%
- Free cash flow
- −37.1%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
Follow AGEN
Alert me
Agenus Inc. (AGEN) Altman Z-score
Agenus Inc.'s Altman Z-score for fiscal 2025 is −14.16, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −14.16 | 1.51 |
| FY2024 | −15.67 | (5.61) |
| FY2023 | −10.07 | (4.00) |
| FY2022 | −6.06 | (3.89) |
| FY2021 | −2.17 | 8.12 |
| FY2020 | −10.29 | 1.25 |
| FY2019 | −11.54 | 2.71 |
| FY2018 | −14.25 | (2.73) |
| FY2017 | −11.52 | (2.79) |
| FY2016 | −8.73 | (5.21) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.84) | — | −1.01 | |
| Retained earnings / total assets | (9.62) | — | −13.47 | |
| EBIT / total assets | (0.09) | — | −0.29 | |
| Market value of equity / total liabilities | 0.19 | — | 0.11 | |
| Sales / total assets | 0.50 | — | 0.50 | |
| Altman Z-score | Distress zone | −14.16 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −38.05 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | 8.2× |
| ENTA Enanta Pharmaceuticals, Inc. compare | −1.4× |
| XFOR X4 Pharmaceuticals, Inc. compare | −1.8× |
| PRLD Prelude Therapeutics Incorporated compare | −6.8× |
| AGEN Agenus Inc. | −14.2× |
| BNTC Benitec Biopharma Limited compare | −66.0× |
| SCTX Scribe Therapeutics Inc. compare | — |
| KYTX Kyverna Therapeutics, Inc. compare | — |
| GALT Galectin Therapeutics Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets